The protein retained similar FX-activating procoagulatory activity as the model compound tTF-NGR, it revealed specific binding to the NG2 target on pericytes and tumor cells, and showed a reproducible antitumor activity against NG2-expressing A549-tumor xenografts. This evidence concerns the gene CSPG4 and neoplasm.